Effective Killing of Acute Myeloid Leukemia by TIM-3 Targeted Chimeric Antigen Receptor T Cells

Acute myeloid leukemia (AML) is an aggressive disease with poor outcomes, overwhelmingly due to relapse. Minimal residual disease (MRD), defined as the persistence of leukemic cells after chemotherapy treatment, is thought to be the major cause of relapse. The origins of relapse in AML have been tra...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Molecular cancer therapeutics 2021-09, Vol.20 (9), p.1702-1712
Hauptverfasser:	Lee, Wen-Hsin Sandy, Ye, Zhiyong, Cheung, Alice M S, Goh, Y P Sharon, Oh, Hsueh Ling Janice, Rajarethinam, Ravisankar, Yeo, Siok Ping, Soh, Mun Kuen, Chan, Esther Hian Li, Tan, Lip Kun, Tan, Soo-Yong, Chuah, Charles, Chng, Wee Joo, Connolly, John E, Wang, Cheng-I
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Apoptosis Cell Proliferation Female Hepatitis A Virus Cellular Receptor 2 - immunology Humans Immunotherapy, Adoptive - methods Leukemia, Myeloid, Acute - immunology Leukemia, Myeloid, Acute - metabolism Leukemia, Myeloid, Acute - pathology Leukemia, Myeloid, Acute - therapy Mice Mice, Inbred NOD Mice, SCID Neoplastic Stem Cells - immunology Neoplastic Stem Cells - metabolism Neoplastic Stem Cells - pathology Tumor Cells, Cultured Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!